FUNDING

Bioneb Pvt Secures GBP £ 220 Million Capital Commitment From the Gem Group

Bioneb will use the funds to continue its research and development of its FDA-approved ultrasonic vibrating mesh drug delivery devices, medical formulations and FDA clinical trials.

Neuromod Successfully Closes €10.5 Million Series B Financing for Tinnitus Treatment Device Lenire®

The investment was led by majority investor Fountain Healthcare Partners, with participation from existing investors Moffett Investment Holdings and Medical Device Resources, with venture-debt provided by Kreos Capital and Silicon Valley Bank.

R3 Vascular Inc. Completes Series A Financing Round and New Chief Executive Officer

The company reports the proceeds will support the company's clinical trial work in developing a next generation of below-the-knee (BTK) interventional therapies for PAD. 

HDT Bio Announces Completion of Seed Financing Round

The vaccine is slated to enter clinical trials in Q4 2020 in partnership with the NIH/NIAID.

HomeDoctor Raises €3,7m Series A Funding Led by Cogito Capital Partners

HomeDoctor, founded in 2016, is a leader in the Polish market in providing online medical consultations and delivery of healthcare services to patients’ homes.

Synklino ApS Raises Seed Round to Develop Breakthrough Infection Treatment for Transplant Patients

The company is a spinout from the University of Copenhagen and the Technical University of Denmark established to develop groundbreaking therapies against devastating viral infections.

Hyprevention Raises New Financing to Commercialize Spinal Implant Product V-STRUT© in the USA

Hyprevention CEO Cecile Vienney notes, “We are delighted that our existing investors have shown confidence in our product development efforts and commercialization plans for the US market by increasing their investment in the company."

ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital

This round of financing will be exclusively funded by Shanghai Healthcare Capital ("SHC"), managed by SIIC Capital, where Shanghai Pharma is one of the founding strategic cornerstone LPs.

Pressao Medical Completes Funding

The company has two products under development. The first is BP-ADJUST™, a new device in the form of a wristwatch that monitors blood pressure and heart rate and uses the information to deliver unique energy therapy to control BP. The second product is BP-ADJUST™ CV.
Medical Device News Magazinespot_img